[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
June 2003

Immunobiologic Agents for the Treatment of PsoriasisClinical Research Delivers New Hope for Patients With Psoriasis

Arch Dermatol. 2003;139(6):791-793. doi:10.1001/archderm.139.6.791

PSORIASIS IS a life-disabling disorder in which 8% to 10% of patients aged 18 to 54 years actively contemplate suicide because of their disease.1 Treatments for moderate to severe psoriasis such as UV-B phototherapy, psoralen plus UV-A (PUVA), methotrexate, acitretin, and cyclosporine are generally used only intermittently owing to their toxic effects and/or inconvenience.2 Therefore, patients experience cycles of remission and flare, which they dislike.

First Page Preview View Large
First page PDF preview
First page PDF preview
×